[Hormonal therapy of benign prostatic hyperplasia]

¹Universitätsklinik für Urologie, Innsbruck.

|January 1, 1995

Summary

Transurethral prostatectomy (TURP) remains standard for benign prostatic hyperplasia, but finasteride offers a safe, endocrinological option. This 5-alpha-reductase inhibitor reduces prostate volume and improves flow rates with fewer side effects than hormonal therapies.

Area of Science:

Urology
Endocrinology
Pharmacology

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Vinorelbine in bladder-preserving multimodality treatment for muscle-invasive bladder cancer-a valid option for cisplatin-unfit patients?

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2021

[What should urologists know about SARS-CoV-2? Risk analysis for urological operations and recommendations for action in clinical routine].

Der Urologe. Ausg. A·2020

Trend analysis and regional tumor incidence in Germany for testicular cancer between 2003 and 2014.

Andrology·2019

ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter study.

Prostate cancer and prostatic diseases·2017

[Urolithiasis 2016 : Reliable, effective and low radiation exposure].

Der Urologe. Ausg. A·2016

[Bevacizumab as first-line therapy in metastatic renal cell carcinoma: Progression-free survival for 3 years].

Der Urologe. Ausg. A·2015

See all related articles

Related Experiment Videos

[Hormonal therapy of benign prostatic hyperplasia]

Related Concept Videos

Vinorelbine in bladder-preserving multimodality treatment for muscle-invasive bladder cancer-a valid option for cisplatin-unfit patients?

[What should urologists know about SARS-CoV-2? Risk analysis for urological operations and recommendations for action in clinical routine].

Trend analysis and regional tumor incidence in Germany for testicular cancer between 2003 and 2014.

ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter study.

[Urolithiasis 2016 : Reliable, effective and low radiation exposure].

[Bevacizumab as first-line therapy in metastatic renal cell carcinoma: Progression-free survival for 3 years].

[G-CSF for prophylaxis of neutropenia and febrile neutropenia, anemia in cancer : Guidelines on supportive treatment part 1].

[Multiparametric MRI of the prostate].

[Follow-up in superficial and metastatic bladder cancer].

[Follow-up after urolithiasis management].

[Aftercare and adjuvant therapy for advanced renal cell carcinoma].

Related Experiment Videos

[Hormonal therapy of benign prostatic hyperplasia]

Area of Science:

Related Concept Videos

Related Articles